00:46 , May 11, 2019 |  BioCentury  |  Product Development

Now grown up, independent biotechs bulk up their platforms with more modalities

As the incoming class of independent biotechs look to build on their clinical and commercial successes, a handful are expanding beyond the technology that got them there, bringing in new modalities to complement their platforms...
23:07 , Sep 19, 2018 |  BC Extra  |  Company News

Management tracks: GSK adds Corsico, Enzmann to chair CHMP

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) hired Chris Corsico, CMO of Boehringer Ingelheim GmbH (Ingelheim, Germany), to lead all development activities for the pharma. As SVP development, Corsico will be based at GSK’s R&D hub in Stevenage,...
22:05 , Apr 25, 2018 |  BC Extra  |  Company News

Management tracks: Urovant, Cue

Urology company Urovant Sciences, a subsidiary of Roivant Sciences GmbH (Basel, Switzerland), hired Cornelia Haag-Molkenteller as CMO, Michael McFadden as chief commercial officer, Bryan Smith as general counsel and Christine Ocampo as SVP and chief...
22:51 , Apr 6, 2018 |  BioCentury  |  Finance

Picking season

  Macroeconomic risks, surging volatility and a tail-off in the M&A market since January have done little to change the buyside’s strategy of overweighting small- and mid-cap biotechs. In fact, the 12 investors who spoke...
20:35 , Feb 2, 2018 |  BC Week In Review  |  Financial News

Seattle Genetics prices $690M follow-on

Seattle Genetics Inc. (NASDAQ:SGEN) raised $690 million through the sale of 13.3 million shares at $52 in a bumped-up follow-on underwritten by Barclays and J.P. Morgan. The figures include the sale of a 1.7 million...
20:33 , Feb 2, 2018 |  BC Week In Review  |  Company News

Seattle Genetics buying Cascadian for $614M

Seattle Genetics Inc. (NASDAQ:SGEN) said it will acquire cancer company Cascadian Therapeutics Inc. (NASDAQ:CASC) for $10 per share in cash, or about $614 million. The price is a 69% premium to Cascadian's close of $5.90...
19:19 , Feb 1, 2018 |  BC Extra  |  Financial News

Seattle Genetics prices $600M follow-on

Seattle Genetics Inc. (NASDAQ:SGEN) raised $600 million on Thursday through the sale of 11.5 million shares at $52 in a bumped-up follow-on underwritten by Barclays and J.P. Morgan. The price is a 6% discount to...
20:00 , Jan 31, 2018 |  BC Extra  |  Company News

Seattle Genetics buying Cascadian for $614M, raising cash

Seattle Genetics Inc. (NASDAQ:SGEN) said it will acquire cancer company Cascadian Therapeutics Inc. (NASDAQ:CASC) for $10 per share in cash, or about $614 million. The price is a 69% premium to Cascadian's close of $5.90...
23:20 , Apr 7, 2017 |  BioCentury  |  Finance

Taking notice

  Political overhang during the first quarter kept generalists on the sidelines but provided a buying opportunity for life sciences specialists that led the sector to outperform. With “repeal and replace” in the rearview for...
21:07 , Jan 27, 2017 |  BC Week In Review  |  Financial News

Cascadian Therapeutics completes follow-on

Cancer company Cascadian Therapeutics Inc. (NASDAQ:CASC) raised $82.5 million through the sale of 23.2 million shares at $3.30 and 1,818 shares of series E convertible preferred stock at $3,300 in concurrent underwritten offerings on Jan....